{
    "organizations": [],
    "uuid": "f714f8a3dccdf9f1aff2ae8f139fb017e5979bc8",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-myokardia-doses-first-patient-in-p/brief-myokardia-doses-first-patient-in-pioneer-open-label-extension-study-of-mavacamten-idUSFWN1SH177",
    "ord_in_thread": 0,
    "title": "BRIEF-MyoKardia Doses First Patient In Pioneer Open-Label Extension Study Of Mavacamten",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 10 (Reuters) - MyoKardia Inc:\n* MYOKARDIA DOSES FIRST PATIENT IN PIONEER OPEN-LABEL EXTENSION STUDY OF MAVACAMTEN FOR SYMPTOMATIC, OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-05-10T20:39:00.000+03:00",
    "crawled": "2018-05-11T12:46:25.029+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "myokardia",
        "inc",
        "myokardia",
        "dos",
        "first",
        "patient",
        "pioneer",
        "extension",
        "study",
        "mavacamten",
        "symptomatic",
        "obstructive",
        "hypertrophic",
        "cardiomyopathy",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}